CGTS Corp. Revenue and Competitors
Estimated Revenue & Valuation
- CGTS Corp.'s estimated annual revenue is currently $9M per year.
- CGTS Corp.'s estimated revenue per employee is $136,432
Employee Data
- CGTS Corp. has 66 Employees.
- CGTS Corp. grew their employee count by -1% last year.
CGTS Corp. Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.2M | 35 | 3% | N/A | N/A |
#2 | $3.8M | 32 | 0% | N/A | N/A |
#3 | $9.4M | 69 | -3% | N/A | N/A |
#4 | $3.9M | 33 | -54% | N/A | N/A |
#5 | $4.3M | 36 | 9% | N/A | N/A |
#6 | $4.9M | 40 | 18% | N/A | N/A |
#7 | $37.5M | 226 | 75% | N/A | N/A |
#8 | $15.4M | 102 | 9% | N/A | N/A |
#9 | $0.7M | 9 | N/A | N/A | N/A |
#10 | $34.9M | 211 | 7% | N/A | N/A |
What Is CGTS Corp.?
CGTS CORP INC. and its affiliated companies are specialized in design and implementation of high complexity technological solutions oriented to specific applications, using state-of-the-art technology, continuous innovation and proven quality in processes and results. The companies that make up the CGTS Corp. group are organized around three fundamental business areas: Intelligent and integrated information systems, biometric solutions and complete solutions on VoIP platform.
keywords:N/A
N/A
Total Funding
66
Number of Employees
$9M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CGTS Corp. News
... Inc. (Xcellbio), a leading developer of cell and gene therapy ... CGTs modify a person's genes to treat disease by inactivating or...
... moved to acquire 100% of the shares of BioCentriq, Inc, a US CDMO that designs and develops scalable cell and gene technologies (CGTs).
Cell-gene therapeutics (CGTs) are emerging in the biotech industry and an ... Samsung Biologics and Samsung Venture Investment Corp.
Other Companies in Miami
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.8M | 66 | 20% | N/A |
#2 | $9M | 66 | 16% | N/A |
#3 | $3.5M | 66 | -6% | N/A |
#4 | $13.2M | 66 | 29% | $10M |
#5 | $16.6M | 66 | 18% | N/A |